Zhiguang Li

Zhiguang Li

Auto-generated profile, based on publicly available information

Zhiguang Li

Center of Genome and Personalized Medicine, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, Liaoning, China

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2013 in Immunity
Verified
Journal Article
Closed access
ZCZuojia Chen
Zuojia Chen
JBJoseph Barbi
Joseph Barbi
SBShurui Bu
Shurui Bu
HYHuang-Yu Yang
Huang-Yu Yang
ZLZhiyuan Li
Zhiyuan Li
BLBin Li
Bin Li

1 August 2018 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
XNXuhao Ni
Xuhao Ni
JTJinhui Tao
Jinhui Tao
JBJoseph Barbi
Joseph Barbi
QCQian Chen
Qian Chen
BPBenjamin V. Park
Benjamin V. Park
FPFan Pan
Fan Pan
Regulatory T cells (Treg) are critical for maintaining self-tolerance and immune homeostasis, but their suppressive function can impede effective antitumor immune responses. FOXP3 is a transcription factor expressed in Tregs that is required for their function. However, the pathways and microenvironmental cues governing FOXP3 expression and Treg function are not completely understood. Herein, we report that YAP, a coactivator of the Hippo pathway, is highly expressed in Tregs and bolsters FOXP3 expression and Treg function in vitro and in vivo. This potentiation stemmed from YAP-dependent upregulation of activin signaling, which amplifies TGFβ/SMAD activation in Tregs. YAP deficiency resulted in dysfunctional Tregs unable to suppress antitumor immunity or promote tumor growth in mice. Chemical YAP antagonism and knockout or blockade of the YAP-regulated activin receptor similarly improved antitumor immunity. Thus, we identify YAP as an unexpected amplifier of a Treg-reinforcing pathway with significant potential as an anticancer immunotherapeutic target. Significance: Tregs suppress antitumor immunity, and pathways supporting their function can be novel immunotherapy targets. Here, the selective expression of YAP by Tregs, its importance for their function, and its unexpected enhancement of pro-Treg Activin/SMAD signaling are reported, as are validations of potential cancer-fighting antagonists of YAP and its regulatory targets. Cancer Discov; 8(8); 1026–43. ©2018 AACR. This article is highlighted in the In This Issue feature, p. 899

1 December 2009 in Cellular & Molecular Immunology
Verified
Journal Article
Closed access
PDF file
ZLZhiguang Li
Zhiguang Li
LCLin Chen
Lin Chen
ZQZhihai Qin
Zhihai Qin

7 September 2011 in ACS Nano
Verified
Journal Article
Closed access
YZYongbin Zhang
Yongbin Zhang
YXYang Xu
Yang Xu
ZLZhiguang Li
Zhiguang Li
TCTao Chen
Tao Chen
SLSusan M. Lantz
Susan M. Lantz
SASyed F. Ali
Syed F. Ali

30 October 2008 in Cancer Research
Verified
Journal Article
Open access
PDF file
ZLZhiguang Li
Zhiguang Li
JJJing Jiang
Jing Jiang
ZWZibing Wang
Zibing Wang
JZJinhua Zhang
Jinhua Zhang
MXMingjie Xiao
Mingjie Xiao
ZQZhihai Qin
Zhihai Qin
The increase of interleukin-4 (IL-4) level in tumor environment and the up-regulation of IL-4 receptor (IL-4R) on tumor cells have been long observed. However, their significance for tumor development has not been investigated. Here, we found that endogenous IL-4 promotes tumor growth because neutralizing IL-4 by 11B11 monoclonal antibody (mAb) significantly delayed the growth of MCA205 fibrosarcoma. We also observed that tumor cells with higher IL-4R expression have more chances to survive in immunocompetent mice. To investigate how endogenous IL-4 influences tumor growth, we established a pair of tumor cells with or without IL-4R expression from the common parental cells. IL-4R–competent tumors exhibit increased growth compared with its IL-4R–deficient counterparts when inoculated into syngeneic mice. This growth advantage was still kept in IL-4R knockout mice but was abrogated in mice given i.p. with IL-4 neutralizing mAb. In vitro analyses indicate that IL-4 neither affects the proliferation of tumor cells nor changes the expression of several immune-related molecules, such as MHC-I, Fas, and B7-H3. Nonetheless, IL-4 up-regulates antiapoptotic gene expression in tumor cells and reduces apoptosis of tumor cells in vivo, as evidenced by real-time PCR, immunoblotting, and TUNEL staining. These findings were helpful to understand the long clinical observation and revealed that endogenous IL-4, the product of host immune response, can be used by tumor cells to facilitate their growth. [Cancer Res 2008;68(21):8687–94]

1 March 2009 in Cancer Research
Verified
Journal Article
Open access
PDF file
MXMingjie Xiao
Mingjie Xiao
CWChunhui Wang
Chunhui Wang
JZJinhua Zhang
Jinhua Zhang
ZLZhiguang Li
Zhiguang Li
XZXueqiang Zhao
Xueqiang Zhao
ZQZhihai Qin
Zhihai Qin
IFNγ plays a crucial role in immunity against a variety of transplanted tumors and methylcholanthrene-mediated tumorigenesis in mice. However, it is not clear whether and how endogenous IFNγ influences 7,12-dimethylbenz(a)anthracene (DMBA)–induced and 12-O-tetradecanoylphorbol-13-acetate (TPA)–induced papilloma development. We found here that IFNγ expression was markedly up-regulated shortly after DMBA/TPA application to the skin. Surprisingly, neutralizing IFNγ activity in vivo did not increase but rather decreased tumor development. Furthermore, IFNγ receptor–deficient mice were also more resistant to papilloma development than their counterparts were. IFNγ acted mainly in the promotion stage of papilloma development by enhancing TPA-induced leukocyte infiltration and epidermal hyperproliferation. The up-regulation of tumor necrosis factor α, interleukin (IL)-6, and transforming growth factor β was largely dependent on host IFNγ responsiveness. Remarkably, up-regulation of both IL-17 expression in the skin and T helper 17 (Th17) cell number in draining lymph nodes after DMBA/TPA treatment was dependent on IFNγ signaling. Depletion of IL-17 not only decreased the DMBA/TPA–induced inflammation and keratinocyte proliferation but also delayed papilloma development. These results show that IFNγ, under certain conditions, may promote tumor development by enhancing a Th17-associated inflammatory reaction. [Cancer Res 2009;69(5):2010–7]